Cohn-Cedermark G - Search Results

1

Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.

Tandstad T, Solberg A, Håkansson U, Stahl O, Haugnes HS, Oldenburg J, Dahl O, Kjellman A, Angelsen A, Cohn-Cedermark G; SWENOTECA. Tandstad T, et al. Acta Oncol. 2015 Apr;54(4):493-9. doi: 10.3109/0284186X.2014.953256. Epub 2014 Sep 5. Acta Oncol. 2015. PMID: 25192551

2

Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O. Tandstad T, et al. J Clin Oncol. 2009 May 1;27(13):2122-8. doi: 10.1200/JCO.2008.18.8953. Epub 2009 Mar 23. J Clin Oncol. 2009. PMID: 19307506

3

Sexual function in men treated for testicular cancer.

Eberhard J, Ståhl O, Cohn-Cedermark G, Cavallin-Ståhl E, Giwercman Y, Rylander L, Eberhard-Gran M, Kvist U, Fugl-Meyer KS, Giwercman A. Eberhard J, et al. J Sex Med. 2009 Jul;6(7):1979-89. doi: 10.1111/j.1743-6109.2009.01298.x. Epub 2009 Apr 28. J Sex Med. 2009. PMID: 19453896

4

Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality.

Eberhard J, Ståhl O, Cohn-Cedermark G, Cavallin-Ståhl E, Giwercman Y, Rastkhani H, Rylander L, Eberhard-Gran M, Kvist U, Giwercman A. Eberhard J, et al. J Affect Disord. 2010 May;122(3):260-6. doi: 10.1016/j.jad.2009.06.035. Epub 2009 Aug 4. J Affect Disord. 2010. PMID: 19656574

5

Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.

Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O. Tandstad T, et al. Ann Oncol. 2010 Sep;21(9):1858-1863. doi: 10.1093/annonc/mdq026. Epub 2010 Feb 8. Ann Oncol. 2010. PMID: 20142410 Free article. Clinical Trial.

6

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623

7

Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.

Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G. Tandstad T, et al. J Clin Oncol. 2011 Feb 20;29(6):719-25. doi: 10.1200/JCO.2010.30.1044. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205748

8

Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.

Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E. Olofsson SE, et al. J Clin Oncol. 2011 May 20;29(15):2032-9. doi: 10.1200/JCO.2010.29.1278. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21482994 Clinical Trial.

9

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).

Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G. Haugnes HS, et al. Acta Oncol. 2012 Feb;51(2):168-76. doi: 10.3109/0284186X.2011.641507. Epub 2011 Dec 19. Acta Oncol. 2012. PMID: 22175254

10

Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer.

Brokken LJ, Lundberg-Giwercman Y, Rajpert De-Meyts E, Eberhard J, Ståhl O, Cohn-Cedermark G, Daugaard G, Arver S, Giwercman A. Brokken LJ, et al. Mol Cell Endocrinol. 2012 Apr 4;351(2):279-85. doi: 10.1016/j.mce.2011.12.018. Epub 2012 Jan 5. Mol Cell Endocrinol. 2012. PMID: 22245602

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page